Premium
Refractory palmoplantar pustulosis succesfully treated with apremilast
Author(s) -
Carrascosa de Lome Raquel,
Conde Montero Elena,
Cueva Dobao Pablo
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13230
Subject(s) - apremilast , palmoplantar pustulosis , medicine , dermatology , psoriasis , refractory (planetary science) , psoriatic arthritis , plaque psoriasis , physics , astrobiology
Palmoplantar pustulosis is a chronic inflammatory disease which characterized by a eruption of sterile pustules on the palms and soles. Apremilast is an oral phosphodiesterase‐4 inhibitor which is approved for the treatment of chronic plaque psoriasis and psoriatic arthritis. However, no clinical trial has been performed to confirm the efficacy of apremilast for palmoplantar pustulosis yet. Moreover, there are very few cases of this disease treated with apremilast. Herein, we describe a case of a refractory palmoplantar pustulosis succesfully treated with apremilast.